• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Alpha Tau Medical Ltd. - Ordinary Shares (NQ:DRTS)

    9.240 +0.050 (+0.54%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jun 10, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 404,074
    Open 8.860
    Bid (Size) 9.250 (200)
    Ask (Size) 9.680 (1,800)
    Prev. Close 9.190
    Today's Range 8.810 - 9.479
    52wk Range 2.850 - 11.62
    Shares Outstanding 68,575,397
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Alpha Tau and Tolmar Announce Strategic Collaboration to Bring Alpha DaRT® Therapy to U.S. Urological Cancer Patients
    From Alpha Tau Medical Ltd.; Tolmar Inc.
    Via GlobeNewswire
    News headline image
    Alpha Tau Announces Strong Overall Survival Results from Alpha DaRT® Pancreatic Cancer Studies Presented at 2026 ASCO Annual Meeting
    From Alpha Tau Medical Ltd.
    Via GlobeNewswire

    Performance

    YTD
    +91.3%
    +91.3%
    1 Month
    -10.6%
    -10.6%
    3 Month
    +35.1%
    +35.1%
    6 Month
    +118.4%
    +118.4%
    1 Year
    +195.7%
    +195.7%

    More News

    Read More
    News headline image
    Alpha Tau Medical Sets Up Catalyst-Rich 2026 as Key Cancer Trial Data Nears ↗
    Via MarketBeat
    News headline image
    Alpha Tau Medical Shares Early REGAIN Data: 2 Complete Responses in Glioblastoma Study ↗
    Via MarketBeat
    Get insights into the top gainers and losers of Monday's pre-market session. ↗
    Via Chartmill
    News headline image
    Alpha Tau Announces Groundbreaking Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial, with 100% Local Disease Control, 67% Complete Response Rate, and Favorable Safety Profile Observed - Conference Call Scheduled for 8:30am ET
    From Alpha Tau Medical Ltd.
    Via GlobeNewswire
    News headline image
    Alpha Tau Completes Patient Enrollment in its U.S. Pivotal Skin Cancer Study, Advancing Towards Goal of FDA Approval of Alpha DaRT® to Treat Recurrent Cutaneous Squamous Cell Carcinoma
    From Alpha Tau Medical Ltd.
    Via GlobeNewswire
    News headline image
    Alpha Tau Announces Upcoming Podium Presentation at the AHNS 12th International Conference on Head and Neck Cancer Showcasing Study Results of Alpha DaRT® Head and Neck Cancer Combination with Pembrolizumab
    From Alpha Tau Medical Ltd.
    Via GlobeNewswire
    News headline image
    Alpha Tau Announces 100% Local Disease Control Rate and Favorable Safety Profile Observed in Alpha DaRT® Pancreatic Cancer Trials Presented at DDW 2026
    From Alpha Tau Medical Ltd.
    Via GlobeNewswire
    News headline image
    Alpha Tau Announces Presentation of Pancreatic Cancer Data at Upcoming ASCO Annual Meeting, Showcasing Combined Results from Three Alpha DaRT Pancreatic Cancer Studies
    From Alpha Tau Medical Ltd.
    Via GlobeNewswire
    News headline image
    Alpha Tau Announces FDA Approval of IDE Supplement to Expand Alpha DaRT® IMPACT Trial to Patients with Pancreatic Cancer Receiving Gemcitabine with Abraxane® (Nab-Paclitaxel)
    From Alpha Tau Medical Ltd.
    Via GlobeNewswire
    News headline image
    Alpha Tau Successfully Treats First Pancreatic Cancer Patient in Europe with Alpha DaRT® in French Multicenter ACAPELLA Clinical Trial
    From Alpha Tau Medical Ltd.
    Via GlobeNewswire
    News headline image
    Alpha Tau to Present at Sidoti March Virtual Small Cap Conference
    From Alpha Tau Medical Ltd.
    Via GlobeNewswire
    News headline image
    Alpha Tau Medical Receives Japanese Marketing Approval for Alpha DaRT® in Unresectable Locally Advanced or Locally Recurrent Head and Neck Cancer
    From Alpha Tau Medical Ltd.
    Via GlobeNewswire
    News headline image
    Alpha Tau Reports New Positive Results in Two Upcoming Presentations at ASCO GI 2026 Symposium Showcasing Immune-Preservation and High Disease Control in Montreal Pancreatic Cancer Alpha DaRT® Study
    From Alpha Tau Medical Ltd.
    Via GlobeNewswire
    News headline image
    Alpha Tau Submits First Pre-Market Approval Module to the FDA for Alpha DaRT® for the Treatment of Recurrent Cutaneous Squamous Cell Carcinoma (cSCC)
    From Alpha Tau Medical Ltd.
    Via GlobeNewswire
    News headline image
    In today's session, these stocks are experiencing unusual volume. ↗
    Via Chartmill
    News headline image
    Alpha Tau Successfully Treats First Patient in its U.S. Trial for Patients with Recurrent Glioblastoma at the James Cancer Hospital at The Ohio State University
    From Alpha Tau Medical Ltd.
    Via GlobeNewswire
    News headline image
    Alpha Tau Announces Presentation of Two Alpha DaRT Pancreatic Cancer Abstracts at Upcoming 2026 ASCO GI Symposium
    From Alpha Tau Medical Ltd.
    Via GlobeNewswire
    News headline image
    Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Locally Recurrent Prostate Cancer
    From Alpha Tau Medical Ltd.
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    Alpha Tau Announces Receipt of Radioactive Material License for its New Hampshire Manufacturing Facility, Advancing Towards Commercial Readiness
    From Alpha Tau Medical Ltd.
    Via GlobeNewswire
    News headline image
    Alpha Tau Successfully Treats First Patient in its U.S. Multi-Center Pancreatic Cancer Clinical Trial
    From Alpha Tau Medical Ltd.
    Via GlobeNewswire
    News headline image
    Alpha Tau Stock Rallies To 3-Month High On Smaller-Than-Feared Q1 Loss: Retail Sentiment Stays Bearish ↗
    Via Stocktwits
    News headline image
    Alpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharmaceuticals
    From Alpha Tau Medical Ltd.
    Via GlobeNewswire

    Frequently Asked Questions

    Is Alpha Tau Medical Ltd. - Ordinary Shares publicly traded?
    Yes, Alpha Tau Medical Ltd. - Ordinary Shares is publicly traded.
    What exchange does Alpha Tau Medical Ltd. - Ordinary Shares trade on?
    Alpha Tau Medical Ltd. - Ordinary Shares trades on the Nasdaq Stock Market
    What is the ticker symbol for Alpha Tau Medical Ltd. - Ordinary Shares?
    The ticker symbol for Alpha Tau Medical Ltd. - Ordinary Shares is DRTS on the Nasdaq Stock Market
    What is the current price of Alpha Tau Medical Ltd. - Ordinary Shares?
    The current price of Alpha Tau Medical Ltd. - Ordinary Shares is 9.240
    When was Alpha Tau Medical Ltd. - Ordinary Shares last traded?
    The last trade of Alpha Tau Medical Ltd. - Ordinary Shares was at 06/10/26 04:00 PM ET
    What is the market capitalization of Alpha Tau Medical Ltd. - Ordinary Shares?
    The market capitalization of Alpha Tau Medical Ltd. - Ordinary Shares is 633.64M
    How many shares of Alpha Tau Medical Ltd. - Ordinary Shares are outstanding?
    Alpha Tau Medical Ltd. - Ordinary Shares has 634M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.